Taken together, these findings suggest that the clinical effects of FFAR4 treatment might be used not only for disorders such as type 2 diabetes and obesity but also the inhibition of osteoclast differentiation and activity. Here, FFAR4 is linked to obesity due to melanocortin 4 receptor deficiency.